Xiong Cai1, Gustavo Pacheco-Rodriguez1, Mary Haughey1, Leigh Samsel2, Suowen Xu1, Hai-Ping Wu1, J Philip McCoy2, Mario Stylianou3, Thomas N Darling4, Joel Moss5. 1. Cardiovascular and Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health. 2. Flow Cytometry Core Facility, National Heart, Lung, and Blood Institute, National Institutes of Health. 3. Office of Biostatistics Research, Division of Cardiovascular Science, National Heart, Lung, and Blood Institute, National Institutes of Health. 4. Department of Dermatology, Uniformed Services University of the Health Sciences, Bethesda, MD. 5. Cardiovascular and Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health. Electronic address: mossj@nhlbi.nih.gov.
Abstract
BACKGROUND: Lymphangioleiomyomatosis (LAM), sporadic or in women with tuberous sclerosis complex (TSC), is characterized by cystic lung destruction, lymphatic involvement (eg, chylous pleural effusions, lymphangioleiomyomas), and renal angiomyolipomas (AMLs). The multisystem manifestations of LAM appear to result from metastatic dissemination of LAM cells bearing inactivating mutations or having loss of heterozygosity (LOH) of the tumor suppressor genes TSC1 or TSC2, which leads to hyperactivation of the mammalian target of rapamycin. Sirolimus slows the decline of lung function, reduces chylous effusions, and shrinks the size of AMLs. The purpose of this study was to determine the effect of sirolimus on circulating LAM cells. METHODS: Cells from blood were isolated by a density-gradient fractionation system and from urine and chylous effusions by centrifugation. Blood cells were incubated with anti-CD45-fluorescein isothiocyanate (FITC) and anti-CD235a-R-phycoerythrin (PE) antibodies, and urine and chylous effusion cells were incubated with anti-CD44v6-FITC and anti-CD9-R-PE antibodies. Cells were sorted and analyzed for TSC2 LOH. RESULTS: LAM cells with TSC2 LOH were identified in 100% of blood specimens and 75% of urine samples from patients before therapy. Over a mean duration of 2.2 ± 0.4 years of sirolimus therapy, detection rates of LAM cells were significantly decreased to 25% in blood (P < .001) and 8% in urine (P = .003). Following therapy, a greater loss of circulating LAM cells was seen in postmenopausal patients (P = .025). CONCLUSIONS: Patients receiving sirolimus had a progressive loss of circulating LAM cells that depended on time of treatment and menopausal status.
BACKGROUND:Lymphangioleiomyomatosis (LAM), sporadic or in women with tuberous sclerosis complex (TSC), is characterized by cystic lung destruction, lymphatic involvement (eg, chylous pleural effusions, lymphangioleiomyomas), and renal angiomyolipomas (AMLs). The multisystem manifestations of LAM appear to result from metastatic dissemination of LAM cells bearing inactivating mutations or having loss of heterozygosity (LOH) of the tumor suppressor genes TSC1 or TSC2, which leads to hyperactivation of the mammalian target of rapamycin. Sirolimus slows the decline of lung function, reduces chylous effusions, and shrinks the size of AMLs. The purpose of this study was to determine the effect of sirolimus on circulating LAM cells. METHODS: Cells from blood were isolated by a density-gradient fractionation system and from urine and chylous effusions by centrifugation. Blood cells were incubated with anti-CD45-fluorescein isothiocyanate (FITC) and anti-CD235a-R-phycoerythrin (PE) antibodies, and urine and chylous effusion cells were incubated with anti-CD44v6-FITC and anti-CD9-R-PE antibodies. Cells were sorted and analyzed for TSC2 LOH. RESULTS: LAM cells with TSC2 LOH were identified in 100% of blood specimens and 75% of urine samples from patients before therapy. Over a mean duration of 2.2 ± 0.4 years of sirolimus therapy, detection rates of LAM cells were significantly decreased to 25% in blood (P < .001) and 8% in urine (P = .003). Following therapy, a greater loss of circulating LAM cells was seen in postmenopausal patients (P = .025). CONCLUSIONS:Patients receiving sirolimus had a progressive loss of circulating LAM cells that depended on time of treatment and menopausal status.
Authors: Markus Guba; Philipp von Breitenbuch; Markus Steinbauer; Gudrun Koehl; Stefanie Flegel; Matthias Hornung; Christiane J Bruns; Carl Zuelke; Stefan Farkas; Matthias Anthuber; Karl-Walter Jauch; Edward K Geissler Journal: Nat Med Date: 2002-02 Impact factor: 53.440
Authors: Jay H Ryu; Joel Moss; Gerald J Beck; Jar-Chi Lee; Kevin K Brown; Jeffrey T Chapman; Geraldine A Finlay; Eric J Olson; Stephen J Ruoss; Janet R Maurer; Thomas A Raffin; Hannah H Peavy; Kevin McCarthy; Angelo Taveira-Dasilva; Francis X McCormack; Nilo A Avila; Rosamma M Decastro; Susan S Jacobs; Mario Stylianou; Barry L Fanburg Journal: Am J Respir Crit Care Med Date: 2005-10-06 Impact factor: 21.405
Authors: Denise M Crooks; Gustavo Pacheco-Rodriguez; Rosamma M DeCastro; J Philip McCoy; Ji-an Wang; Fumiyuki Kumaki; Thomas Darling; Joel Moss Journal: Proc Natl Acad Sci U S A Date: 2004-12-06 Impact factor: 11.205
Authors: Elena A Goncharova; Dmitry A Goncharov; Andrew Eszterhas; Deborah S Hunter; Marilyn K Glassberg; Raymond S Yeung; Cheryl L Walker; Daniel Noonan; David J Kwiatkowski; Margaret M Chou; Reynold A Panettieri; Vera P Krymskaya Journal: J Biol Chem Date: 2002-06-03 Impact factor: 5.157
Authors: Massimo Cristofanilli; G Thomas Budd; Matthew J Ellis; Alison Stopeck; Jeri Matera; M Craig Miller; James M Reuben; Gerald V Doyle; W Jeffrey Allard; Leon W M M Terstappen; Daniel F Hayes Journal: N Engl J Med Date: 2004-08-19 Impact factor: 91.245
Authors: Gustavo Pacheco-Rodriguez; Wendy K Steagall; Denise M Crooks; Linda A Stevens; Hiroshi Hashimoto; Shaowei Li; Ji-an Wang; Thomas N Darling; Joel Moss Journal: Cancer Res Date: 2007-11-01 Impact factor: 12.701
Authors: Wendy K Steagall; Gustavo Pacheco-Rodriguez; Thomas N Darling; Olga Torre; Sergio Harari; Joel Moss Journal: Am J Respir Cell Mol Biol Date: 2018-06 Impact factor: 6.914
Authors: Wendy K Steagall; Li Zhang; Xiong Cai; Gustavo Pacheco-Rodriguez; Joel Moss Journal: Am J Respir Crit Care Med Date: 2015-04-01 Impact factor: 21.405
Authors: Jianhua Yao; Angelo M Taveira-DaSilva; Amanda M Jones; Patricia Julien-Williams; Mario Stylianou; Joel Moss Journal: Am J Respir Crit Care Med Date: 2014-12-01 Impact factor: 21.405
Authors: Elena Lesma; Silvia Ancona; Silvia M Sirchia; Emanuela Orpianesi; Vera Grande; Patrizia Colapietro; Eloisa Chiaramonte; Anna Maria Di Giulio; Alfredo Gorio Journal: J Cell Mol Med Date: 2014-03-07 Impact factor: 5.310